Search

everythinglearnresearchcommunity

for

Search:↓

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

Asian dermatologists are more open to prescribing finasteride, while in some regions, medications like finasteride and minoxidil can be obtained without a prescription. In Europe, particularly France, there are stricter regulations requiring patients to acknowledge potential side effects, but many people find ways to obtain these treatments through various means.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Hair loss discussion mentions Redensyl with 85% success rate and visible regrowth. Users skeptical, prefer Minoxidil, Finasteride, and RU58841.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The user has been using RU58841 for 6 months without noticeable results and is considering dropping it while continuing oral minoxidil, daily dutasteride, and topical minoxidil. Another user suggests visiting a dermatologist to check for other conditions.

The user switched from prescribed topical minoxidil and finasteride to stronger grey market alternatives, hoping for better hair growth but experiencing shedding. Concerns were raised about the legitimacy and safety of grey market products, with suggestions to use prescribed medications instead.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

The user experienced noticeable hair regrowth after using finasteride for 2 years, oral minoxidil for 1 year, and recently starting dermarolling. The right temple shows significant improvement, while the left remains similar.

The user has been using oral finasteride and topical minoxidil for two months and is seeking feedback on progress. Another user confirms there is noticeable progress.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The user is experiencing some hair regrowth after six months on oral minoxidil (3mg), finasteride (1.2mg), and using 1% ketoconazole shampoo twice a week, with no side effects. They are advised to consult a doctor before adjusting doses and to consider blood tests for vitamin and mineral levels.

Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

The conversation is about the possibility of obtaining Pyrilutamide, a hair loss treatment, once it becomes available in China, despite it not being approved by the US FDA yet. The user wants to use Pyrilutamide along with other treatments.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.

The user reported significant hair regrowth after using 1mg finasteride, 5% minoxidil twice daily, and dermarolling every 10 days. Others noted improvements and encouraged continued updates.

The user has experienced significant hair regrowth using finasteride for 7 months and minoxidil for 3.5 months, with many commenters noting visible progress. The user has not experienced side effects and is considering additional treatments like microneedling.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

RU58841 availability on Amazon is questioned for legitimacy. Users discuss its use alongside Minoxidil and Finasteride for hair loss treatment.

A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.